Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.
Elnaggar M, Agte S, Restrepo P, Ram M, Melnekoff D, Adamopoulos C, Stevens MM, Kappes K, Leshchenko V, Verina D, Jagannath S, Poulikakos PI, Parekh S, Laganà A. Elnaggar M, et al. Among authors: melnekoff d. J Hematol Oncol. 2022 Aug 17;15(1):109. doi: 10.1186/s13045-022-01330-3. J Hematol Oncol. 2022. PMID: 35978321 Free PMC article.
Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma.
Laganà A, Perumal D, Melnekoff D, Readhead B, Kidd BA, Leshchenko V, Kuo PY, Keats J, DeRome M, Yesil J, Auclair D, Lonial S, Chari A, Cho HJ, Barlogie B, Jagannath S, Dudley JT, Parekh S. Laganà A, et al. Among authors: melnekoff d. Leukemia. 2018 Jan;32(1):120-130. doi: 10.1038/leu.2017.197. Epub 2017 Jun 23. Leukemia. 2018. PMID: 28642592
Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach.
Laganà A, Beno I, Melnekoff D, Leshchenko V, Madduri D, Ramdas D, Sanchez L, Niglio S, Perumal D, Kidd BA, Miotto R, Shaknovich R, Chari A, Cho HJ, Barlogie B, Jagannath S, Dudley JT, Parekh S. Laganà A, et al. Among authors: melnekoff d. JCO Precis Oncol. 2018;2018:PO.18.00019. doi: 10.1200/PO.18.00019. Epub 2018 Aug 8. JCO Precis Oncol. 2018. PMID: 30706044 Free PMC article.
Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma.
Perumal D, Imai N, Laganà A, Finnigan J, Melnekoff D, Leshchenko VV, Solovyov A, Madduri D, Chari A, Cho HJ, Dudley JT, Brody JD, Jagannath S, Greenbaum B, Gnjatic S, Bhardwaj N, Parekh S. Perumal D, et al. Among authors: melnekoff d. Clin Cancer Res. 2020 Jan 15;26(2):450-464. doi: 10.1158/1078-0432.CCR-19-2309. Epub 2019 Dec 19. Clin Cancer Res. 2020. PMID: 31857430 Free PMC article.
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma.
Van Oekelen O, Parekh S, Cho HJ, Vishnuvardhan N, Madduri D, Richter J, Ip C, Lau K, Florendo E, Mancia IS, Thomas J, Verina D, Chan E, Zarychta K, La L, Strumolo G, Melnekoff DT, Leshchenko VV, Kim-Schulze S, Couto S, Wang M, Pierceall WE, Thakurta A, Laganà A, Jagannath S, Chari A. Van Oekelen O, et al. Among authors: melnekoff dt. Leuk Lymphoma. 2020 Sep;61(9):2208-2215. doi: 10.1080/10428194.2020.1805111. Epub 2020 Aug 19. Leuk Lymphoma. 2020. PMID: 32812822 Clinical Trial.
Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications.
Bhalla S, Melnekoff DT, Aleman A, Leshchenko V, Restrepo P, Keats J, Onel K, Sawyer JR, Madduri D, Richter J, Richard S, Chari A, Cho HJ, Dudley JT, Jagannath S, Laganà A, Parekh S. Bhalla S, et al. Among authors: melnekoff dt. Sci Adv. 2021 Nov 19;7(47):eabg9551. doi: 10.1126/sciadv.abg9551. Epub 2021 Nov 17. Sci Adv. 2021. PMID: 34788103 Free PMC article.
A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma.
Restrepo P, Bhalla S, Ghodke-Puranik Y, Aleman A, Leshchenko V, Melnekoff DT, Agte S, Jiang J, Madduri D, Richter J, Richard S, Chari A, Cho HJ, Jagannath S, Walker CJ, Landesman Y, Laganà A, Parekh S. Restrepo P, et al. Among authors: melnekoff dt. JCO Precis Oncol. 2022 Jun;6:e2200147. doi: 10.1200/PO.22.00147. JCO Precis Oncol. 2022. PMID: 35704796 Free PMC article.
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma.
Mouhieddine TH, Van Oekelen O, Melnekoff DT, Li J, Ghodke-Puranik Y, Lancman G, Thibaud S, Pan D, Rajeeve S, Agte S, Aleman A, Sanchez L, Richard S, Rossi A, Richter J, Cho HJ, Rodriguez C, Lagana A, Moshier E, Chari A, Jagannath S, Parekh S. Mouhieddine TH, et al. Among authors: melnekoff dt. Blood Adv. 2023 Mar 28;7(6):1056-1064. doi: 10.1182/bloodadvances.2022007923. Blood Adv. 2023. PMID: 36018226 Free PMC article. Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 36164185
14 results